Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The co
| Current Price | ₹266.95 |
|---|---|
| Market Cap | ₹166 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 47.1 |
| Return on Equity | 7.91% |
| 52-Week Range | ₹159.00 – ₹317.00 |
| Beta (1Y) | 0.38 |
Auro Laboratories Ltd. is trading at ₹266.95, with a market capitalisation of ₹166 Cr.
Auro Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Auro Laboratories Ltd. has a P/E of 47.1 and a return on equity of 7.91%.